CA2970739C - Use of 3,5-dihydroxy-4-isopropyl-trans-stilbene, for treating skin conditions - Google Patents

Use of 3,5-dihydroxy-4-isopropyl-trans-stilbene, for treating skin conditions Download PDF

Info

Publication number
CA2970739C
CA2970739C CA2970739A CA2970739A CA2970739C CA 2970739 C CA2970739 C CA 2970739C CA 2970739 A CA2970739 A CA 2970739A CA 2970739 A CA2970739 A CA 2970739A CA 2970739 C CA2970739 C CA 2970739C
Authority
CA
Canada
Prior art keywords
compound
stilbene
dihydroxy
isopropyl
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2970739A
Other languages
English (en)
French (fr)
Other versions
CA2970739A1 (en
Inventor
Javier Cote-Sierra
Susan H. Smith
Steven M. Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermavant Sciences GmbH
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of CA2970739A1 publication Critical patent/CA2970739A1/en
Application granted granted Critical
Publication of CA2970739C publication Critical patent/CA2970739C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2970739A 2014-12-12 2015-12-09 Use of 3,5-dihydroxy-4-isopropyl-trans-stilbene, for treating skin conditions Active CA2970739C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090908P 2014-12-12 2014-12-12
US62/090,908 2014-12-12
PCT/IB2015/059490 WO2016092493A1 (en) 2014-12-12 2015-12-09 Novel method of use

Publications (2)

Publication Number Publication Date
CA2970739A1 CA2970739A1 (en) 2016-06-16
CA2970739C true CA2970739C (en) 2023-10-03

Family

ID=55025296

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2970739A Active CA2970739C (en) 2014-12-12 2015-12-09 Use of 3,5-dihydroxy-4-isopropyl-trans-stilbene, for treating skin conditions

Country Status (11)

Country Link
US (1) US10376475B2 (cg-RX-API-DMAC7.html)
EP (1) EP3229840B1 (cg-RX-API-DMAC7.html)
JP (3) JP7313117B2 (cg-RX-API-DMAC7.html)
KR (1) KR102607222B1 (cg-RX-API-DMAC7.html)
AR (1) AR102973A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015358910B2 (cg-RX-API-DMAC7.html)
CA (1) CA2970739C (cg-RX-API-DMAC7.html)
DK (1) DK3229840T5 (cg-RX-API-DMAC7.html)
ES (1) ES2829637T3 (cg-RX-API-DMAC7.html)
TW (1) TWI692357B (cg-RX-API-DMAC7.html)
WO (1) WO2016092493A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
CA2986251A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Topical pharmaceutical compositions
US20170231922A1 (en) * 2016-02-16 2017-08-17 Horizon GenoMed Therapeutics, Inc 3, 5-dihydroxy-4-isopropylstilbene (dhis) as miticidal agent and its therapeutic uses
CN111511357B (zh) 2017-11-10 2024-04-09 德玛万科学有限责任公司 用于制备他品洛夫的方法
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
US20220054467A1 (en) * 2019-02-25 2022-02-24 Sol-Gel Technologies Ltd. Treatment of psoriasis with topical tapinarof-tazarotene combination compositions
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
US20220287990A1 (en) * 2019-07-24 2022-09-15 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
US20220331268A1 (en) * 2019-09-26 2022-10-20 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
WO2021100051A1 (en) * 2019-11-24 2021-05-27 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经系统相关疾病的化合物
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5747482A (en) 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
EP1248774B1 (en) 1999-12-06 2009-10-07 Welichem Biotech Inc. Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors
US7321050B2 (en) * 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
CA2501663A1 (en) * 2002-10-01 2004-04-15 Welichem Biotech Inc. Stilbene derivatives having an immune-modulating activity
FR2917427B1 (fr) 2007-06-18 2009-08-21 Galderma Res & Dev Inhibiteurs de tace dans le traitement de l'acne
US9308239B2 (en) * 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
CN101531571B (zh) 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
CN101633606B (zh) 2009-08-13 2014-08-27 河北科技大学 盐酸非均相氯代合成茋类化合物的方法
CN101648851B (zh) 2009-09-03 2012-10-10 河北科技大学 (e)-3,5-二羟基-4-异丙基二苯乙烯的清洁制备方法
CN101830764A (zh) 2010-05-05 2010-09-15 河北科技大学 利用Pfitzner-moffatt氧化反应合成茋类化合物的方法
CN101838173A (zh) 2010-05-07 2010-09-22 河北科技大学 利用Kornblum氧化反应合成茋类化合物的方法
JP6279467B2 (ja) 2011-06-27 2018-02-14 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規ｔｈ１７分化マーカーおよびその使用

Also Published As

Publication number Publication date
DK3229840T5 (da) 2020-11-16
AU2015358910A1 (en) 2017-06-29
AU2015358910B2 (en) 2019-01-24
JP2021152018A (ja) 2021-09-30
WO2016092493A1 (en) 2016-06-16
JP2017537936A (ja) 2017-12-21
DK3229840T3 (da) 2020-11-09
KR20170095928A (ko) 2017-08-23
TW201639548A (zh) 2016-11-16
CA2970739A1 (en) 2016-06-16
TWI692357B (zh) 2020-05-01
EP3229840A1 (en) 2017-10-18
US10376475B2 (en) 2019-08-13
AR102973A1 (es) 2017-04-05
ES2829637T3 (es) 2021-06-01
JP2023123554A (ja) 2023-09-05
JP7313117B2 (ja) 2023-07-24
US20170360719A1 (en) 2017-12-21
EP3229840B1 (en) 2020-09-09
KR102607222B1 (ko) 2023-11-29

Similar Documents

Publication Publication Date Title
CA2970739C (en) Use of 3,5-dihydroxy-4-isopropyl-trans-stilbene, for treating skin conditions
Han et al. The antimicrobial effect of CEN1HC-Br against Propionibacterium acnes and its therapeutic and anti-inflammatory effects on acne vulgaris
Lee et al. Protease-activated receptor-2 mediates the expression of inflammatory cytokines, antimicrobial peptides, and matrix metalloproteinases in keratinocytes in response to Propionibacterium acnes
Yuan et al. Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2/STAT3 signal pathways
EP2379085B1 (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
Zhang et al. Puerarin prevents LPS-induced osteoclast formation and bone loss via inhibition of Akt activation
GB2542797A (en) Use of cannabinoids in the treatment of inflammatory skin diseases
JP2018115168A (ja) プロバイオティクス細菌
Téllez-Pérez et al. Cholecalciferol (vitamin D) differentially regulates antimicrobial peptide expression in bovine mammary epithelial cells: implications during Staphylococcus aureus internalization
Wang et al. Thymol activates TRPM8-mediated Ca2+ influx for its antipruritic effects and alleviates inflammatory response in Imiquimod-induced mice
JP2012531448A (ja) 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
An et al. The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis
RU2687151C2 (ru) Тетрапептиды, полученные из с-х-с-хемокинов человека, подходящие для лечения различных состояний кожи
JP2018080199A (ja) カルシウムフラックスアゴニスト及びその方法
Füller et al. Anti-proliferative and anti-migratory effects of hyperforin in 2D and 3D artificial constructs of human dermal fibroblasts–a new option for hypertrophic scar treatment?
AU2015201042A1 (en) Therapeutic Method
WO2012105706A1 (ja) ケロイド治療剤
US20220118020A1 (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture and method of use
CA3064050A1 (en) Extracts from arthrospira and uses thereof
TW201711696A (zh) 用於促進傷口癒合的吳郭魚抗菌胜肽
Tran Effect of Oxyresveratrol on Inflammatory Skin Diseases||
Naresh EVALUATION OF WOUND HEALING POTENTIAL OF CURCUMIN AND DEFEROXAMINE COMBINATION IN CUTANEOUS WOUND HEALING IN RATS THESIS
WO2025111413A1 (en) Treatment for skin disorders
오윤실 Inhibitory Effects of Orobol on Heat-killed Propionibacterium acnes-induced Inflammation and Hyperproliferation of HaCaT Keratinocytes
Helwa The Mechanism of monomethylfumarate as an anti-psoriatic agent

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201020

EEER Examination request

Effective date: 20201020

EEER Examination request

Effective date: 20201020

EEER Examination request

Effective date: 20201020

EEER Examination request

Effective date: 20201020

EEER Examination request

Effective date: 20201020

EEER Examination request

Effective date: 20201020

EEER Examination request

Effective date: 20201020

EEER Examination request

Effective date: 20201020